Olufunmilayo I. Olopade
A5057209864- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Nutrition, Genetics, and Disease
- Global Cancer Incidence and Screening
- Genetic Associations and Epidemiology
- Breast Cancer Treatment Studies
- Ovarian cancer diagnosis and treatment
- DNA Repair Mechanisms
- Genetic factors in colorectal cancer
- Epigenetics and DNA Methylation
- Genomic variations and chromosomal abnormalities
- Cancer Risks and Factors
- RNA modifications and cancer
- CRISPR and Genetic Engineering
- Cancer-related Molecular Pathways
- Radiomics and Machine Learning in Medical Imaging
- Molecular Biology Techniques and Applications
- Genetics, Bioinformatics, and Biomedical Research
- Gene expression and cancer classification
- AI in cancer detection
- Cancer-related molecular mechanisms research
- HER2/EGFR in Cancer Research
- Ethics in Clinical Research
- Economic and Financial Impacts of Cancer
- Cancer Cells and Metastasis
University of Chicago
2016-2025
Cancer Genetics (United States)
2016-2025
University of Chicago Medical Center
2016-2025
Chicago Department of Public Health
2011-2024
Center for Global Health
2013-2023
University of Douala
2023
George Washington University
2023
University of Ibadan
2009-2022
University of Chicago Medicine Comprehensive Cancer Center
2021
UC Irvine Health
2021
Data concerning the efficacy of bilateral prophylactic oophorectomy for reducing risk gynecologic cancer in women with BRCA1 or BRCA2 mutations are limited. We investigated whether this procedure reduces cancers coelomic epithelium and breast who carry such mutations.
Mastectomy and salpingo-oophorectomy are widely used by carriers of BRCA1 or BRCA2 mutations to reduce their risks breast ovarian cancer.To estimate risk mortality reduction stratified mutation prior cancer status.Prospective, multicenter cohort study 2482 women with ascertained between 1974 2008. The was conducted at 22 clinical research genetics centers in Europe North America assess the relationship risk-reducing mastectomy outcomes. were followed up until end 2009.Breast risk,...
Abstract Background Validation of a novel gene expression signature in independent data sets is critical step the development clinically useful test for cancer patient risk-stratification. However, validation often unconvincing because size set typically small. To overcome this problem we used publicly available breast and approach to fusion, order validate new tumor intrinsic list. Results A 105-tumor training containing 26 sample pairs was derive This list contained 1300 genes...
Abstract Background Although numerous mouse models of breast carcinomas have been developed, we do not know the extent to which any faithfully represent clinically significant human phenotypes. To address this need, characterized mammary tumor gene expression profiles from 13 different murine using DNA microarrays and compared resulting data those tumors. Results Unsupervised hierarchical clustering analysis showed that six (TgWAP- Myc , TgMMTV- Neu PyMT TgWAP- Int3 Tag TgC3(1)- ) yielded...
Data on the efficacy of bilateral prophylactic mastectomy for breast cancer risk reduction in women with BRCA1 and BRCA2 (BRCA1/2) mutations are limited, despite clinical use this risk-management strategy. Thus, we estimated degree after surgery who carry these mutations.Four hundred eighty-three disease-associated germline BRCA1/2 were studied occurrence cancer. Cases mutation carriers underwent followed prospectively from time their center ascertainment surgery, analyses performed both...
Breast cancer is a heterogeneous disease with known expression-defined tumor subtypes. DNA copy number studies have suggested that tumors within gene expression subtypes share similar Copy aberrations (CNA) and CNA can be used to further sub-divide classes. To gain insights into the etiologies of intrinsic subtypes, we classified according subtype next identified subtype-associated using novel method called SWITCHdna, training set 180 validation 359 tumors. Fisher's exact tests, Chi-square...
To estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers after diagnosis to determine which factors are predictive a second primary cancer.Patients included 491 women with stage I or II cancer, for whom mutation had been identified family. Patients were followed from initial until mastectomy, death, last follow-up.The actuarial was 29.5% at 10 years. Factors that reduced presence (v mutation; hazard ratio [HR], 0.73; 95% CI, 0.47 1.15); age 50 years older first <or= 49...
Linkage analysis of ten Utah kindreds and one Texas kindred with multiple cases cutaneous malignant melanoma (CMM) provided evidence that a locus for familial susceptibility is in the chromosomal region 9p13-p22. The genetic markers analyzed reside candidate on chromosome 9p21, previously implicated by presence homozygous deletions tumors germline deletion an individual eight independent melanomas. Multipoint linkage was performed between (MLM) two short tandem repeat markers, D9S126...
The genetic and clinical heterogeneity of breast cancer makes the identification effective therapies challenging. We designed I-SPY 2, a phase multicenter, adaptively randomized trial to screen multiple experimental regimens in combination with standard neoadjuvant chemotherapy for cancer. goal is match responding subtypes. report results veliparib, poly(ADP-ribose) polymerase (PARP) inhibitor, combined carboplatin.In this ongoing trial, women are eligible participation if they have stage II...
Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists.
Neoadjuvant chemotherapy for breast cancer provides critical information about tumor response; how best to leverage this predicting recurrence-free survival (RFS) is not established. The I-SPY 1 TRIAL (Investigation of Serial Studies Predict Your Therapeutic Response With Imaging and Molecular Analysis) was a multicenter study integrating clinical, imaging, genomic data evaluate pathologic response, RFS, their relationship predictability based on biomarkers.
Purpose Bilateral prophylactic oophorectomy (BPO) is widely used for cancer risk reduction in women with BRCA1/2 mutations. Many premenopausal choose to take hormone replacement therapy (HRT) after undergoing BPO abrogate immediate symptoms of surgically-induced menopause. Thus, we evaluated whether the breast conferred by mutation carriers altered use post-BPO HRT. Methods We identified a prospective cohort 462 disease-associated germline mutations at 13 medical centers evaluate and without...
Compared with white women, black women experience a disproportionate burden of aggressive breast cancer for reasons that remain unknown and understudied. In the first study its kind, we determined distribution molecular subtypes invasive tumors in indigenous West Africa.The comprised 507 patients diagnosed between 1996 2007 at six geographic regions Nigeria Senegal. Formalin-fixed paraffin-embedded sections were constructed into tissue microarrays immunostained 15 antibodies. Five...
MYC is a key regulator of cell growth, proliferation, metabolism, differentiation, and apoptosis. deregulation contributes to breast cancer development progression associated with poor outcomes. Multiple mechanisms are involved in cancer, including gene amplification, transcriptional regulation, mRNA protein stabilization, which correlate loss tumor suppressors activation oncogenic pathways. The heterogeneity increasingly recognized. Breast has been classified into 5 or more subtypes based...
PURPOSE To estimate age-specific relative and absolute cancer risks of breast to ovarian, pancreatic, male breast, prostate, colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these have not been extensively characterized. METHODS We analyzed data from 524 families PVs 21 countries. Complex segregation analysis was used (RRs; country-specific population incidences) cancers. The models allowed for residual familial aggregation ovarian were adjusted the...
We compared the outcome of breast-conserving surgery and radiotherapy in BRCA1/2 mutation carriers with breast cancer versus that matched sporadic controls.A total 160 were 445 controls cancer. Primary end points rates in-breast tumor recurrence (IBTR) contralateral cancers (CBCs). Median follow-up was 7.9 years for 6.7 controls.There no significant difference IBTR overall between controls; 10- 15-year estimates 12% 24% 9% 17% controls, respectively (hazard ratio [HR], 1.37; P = .19)....
Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and judge the impact of therapy recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging signatures, outcomes pathologic complete (pCR) RFS. current analysis was performed data from who had profiles did not receive trastuzumab. various classifiers tested were highly correlated. Categorization signatures...